Leadership Team

Charlotte (Charlie) Newman joined Cardurion as Chief Business Officer in January 2025. She has over 25 years of biopharmaceutical industry experience, and most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals.

As CBO of Agios, Ms. Newman was responsible for the strategy and execution of the company’s portfolio as it evolved to focus on potential first and best-in-class therapeutics to address diseases of high unmet need in non-malignant hematology. Leading business development, she was instrumental in balancing portfolio investments, expanding the company’s portfolio and identifying paths to value inflection. She held previous roles at Agios as senior vice president of portfolio leadership and as vice president of rare disease program.

Previously, Ms. Newman served at Biogen as vice president and asset executive, Alzheimer’s disease, and vice president, R&D portfolio leadership. Earlier in her career, she worked in roles in clinical development and operations at Biogen, Provensis Ltd, and G.D. Searle and Company.

Ms. Newman earned a Bachelor’s degree in Animal Physiology with Biochemistry from the University of Leicester in the UK.